Trials / Completed
CompletedNCT02820324
Study of Oliceridine (TRV130) for the Treatment of Moderate to Severe Acute Pain After Abdominoplasty
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo and Active-Controlled Study of Oliceridine (TRV130) for the Treatment of Moderate to Severe Acute Pain After Abdominoplasty
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 407 (actual)
- Sponsor
- Trevena Inc. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Accepted
Summary
The primary objective is to evaluate the analgesic efficacy of intravenous (IV) oliceridine administered as needed (PRN) compared with placebo in patients with moderate to severe acute pain after abdominoplasty.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Oliceridine | |
| DRUG | Placebo | |
| DRUG | Morphine |
Timeline
- Start date
- 2016-05-01
- Primary completion
- 2016-12-01
- Completion
- 2017-01-01
- First posted
- 2016-06-30
- Last updated
- 2020-10-23
- Results posted
- 2020-10-23
Locations
5 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02820324. Inclusion in this directory is not an endorsement.